ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0084

Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts

Keita Okamoto1, Yasuto Araki2, Yoshimi Aizaki2, Hiroshi Kajiyama3, Kazuhiro Yokota2, Yu Funakubo2, Yuho Kadono4, Yuji Akiyama5 and Toshihide Mimura6, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-chou, Iruma-gun, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, 4Department of Orthopaedic Surgery, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, 5Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, 6Saitama Seikeikai Hospital, Higashimatsuyama, Saitama, Japan

Meeting: ACR Convergence 2025

Keywords: chemokines, Epigenetics, rheumatoid arthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASFs) produce various matrix metalloproteinases (MMPs), cytokines, and chemokines. Histone lysine methylation has been shown to play an important role in the activation of RASFs. We reported that histone lysine methyltransferases (HKMTs), including myeloid/lymphoid or mixed-lineage leukemia 1 (MLL1) and MLL3, are aberrantly expressed in RASFs (PMID: 29465369). MLL1 and MLL3 catalyze histone H3 lysine 4 (H3K4) methylation and are each part of complex proteins associated with Set1 (COMPASS)-like complexes that include WD repeat domain 5 (WDR5) (PMID: 22663077). WDR5 is essential for methylation of H3K4 by MLL1 and MLL3. We investigated the role of MLL1 and MLL3 in RASFs in terms of epigenetic mechanisms of RA pathogenesis.

Methods: Human SFs were isolated from synovial tissues obtained from RA or osteoarthritis (OA) patients undergoing total knee arthroplasty. MLL1 and MLL3 mRNA levels of the above SFs were determined after tumor necrosis factor alpha (TNFα) stimulation. Trimethylation of H3K4 (H3K4me3) is present at the promoters of actively transcribed genes. We investigated changes in mRNA levels of RA-associated genes (matrix-degrading enzymes, cytokines, and chemokines) and H3K4me3 levels in the promoters of these genes upon small interfering RNA-mediated depletion of MLL1 and MLL3 in RASFs. We then determined the levels of H3K4me3 and mRNAs after treatment with MM-102, a WDR5 inhibitor. H3K4me3 levels in the gene promoters were also compared between RASFs and OASFs. Differences between unpaired or paired groups were evaluated using the Mann–Whitney U test or the Wilcoxon signed-rank test, respectively.

Results: MLL1 and MLL3 mRNA levels were significantly higher in RASFs than in OASFs after TNFα stimulation. MLL1 depletion significantly decreased the mRNA levels of several genes of cytokines (IL-6 and IL-15) and chemokines (CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1) in RASFs (Figure 1A). Correspondingly, MLL1 depletion significantly reduced H3K4me3 levels in the promoters of the cytokine and chemokine genes in RASFs (Figure 2). These results indicate that MLL1 activates the cytokine and chemokine genes by increasing promoter H3K4me3 levels in RASFs. Interestingly, MLL3 depletion also suppressed the mRNA levels of CCL5, CXCL10, and CXCL11 genes in RASFs (Figure 1B). However, H3K4me3 levels in the promoters of the chemokine genes were not altered by MLL3 depletion in RASFs (Figure 2). Since it has been reported that MLL3 is involved in the generation of H3K4 monomethylation (H3K4me1) in the enhancers of actively transcribed genes (PMID: 24081332), our results suggest that MLL3 may activate CCL5, CXCL10, and CXCL11 genes by increasing enhancer H3K4me1 levels. MM-102 significantly decreased promoter H3K4me3 and mRNA levels of CCL5, CXCL9, CXCL10, and CXCL11 genes in RASFs. H3K4me3 levels in the promoters of IL-6, IL-15, CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1 genes were significantly higher in RASFs than in OASFs.

Conclusion: This study elucidated the epigenetic mechanism by which MLL1 and MLL3 cooperate to activate chemokine genes in RASFs. These findings may lead to new treatments such as targeting histone methyltransferases for RA.

Supporting image 1

Supporting image 2


Disclosures: K. Okamoto: None; Y. Araki: None; Y. Aizaki: None; H. Kajiyama: None; K. Yokota: None; Y. Funakubo: None; Y. Kadono: None; Y. Akiyama: None; T. Mimura: None.

To cite this abstract in AMA style:

Okamoto K, Araki Y, Aizaki Y, Kajiyama H, Yokota K, Funakubo Y, Kadono Y, Akiyama Y, Mimura T. Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/regulation-of-the-same-chemokine-gene-transcription-by-different-histone-lysine-methyltransferases-mll1-and-mll3-in-rheumatoid-arthritis-synovial-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regulation-of-the-same-chemokine-gene-transcription-by-different-histone-lysine-methyltransferases-mll1-and-mll3-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology